Back to GetFilings.com



 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 10-Q

 

(Mark One)

 

ý

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 29, 2003

 

or

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from          to          

 

Commission File Number: 0-28236

 

INVISION TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation or organization)

 

94-3123544

(I.R.S. Employer Identification No.)

 

7151 Gateway Boulevard, Newark, CA 94560

(Address of principal executive offices, including zip code)

 

(510) 739-2400

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ý   No  o

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).  Yes  ý   No  o

 

On July 15, 2003, there were 17,266,870 shares of the registrant’s common stock outstanding.

 

 



 

InVision Technologies, Inc.

Form 10-Q

INDEX

 

PART  I.  FINANCIAL INFORMATION

 

Item

 

 

 

 

1.

Financial Statements

 

 

 

 

a.

Condensed Consolidated Balance Sheets – June 29, 2003 and December 31, 2002

 

 

 

 

b.

Condensed Consolidated Statements of Operations - Three and six months ended June 29, 2003 and June 30, 2002

 

 

 

 

c.

Condensed Consolidated Statements of Cash Flows - Six months ended June 29, 2003 and June 30, 2002

 

 

 

 

d.

Notes to Condensed Consolidated Financial Statements

 

 

 

2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

 

3.

Quantitative and Qualitative Disclosures about Market Risk

 

 

4.

Controls and Procedures

 

 

PART  II.  OTHER INFORMATION

 

Item

 

1.

Legal Proceedings

 

 

4.

Submission of Matters to a Vote of Security Holders

 

 

5.

Other Information

 

 

6.

Exhibits and Reports on Form 8-K

 

 

Signature Page

 

 

Certification of Dr. Sergio Magistri

 

 

Certification of Ross Mulholland

 

InVision, Quantum Magnetics, QScan, Yxlon, CTX, CTX 5500 DS and CTX 9000 DSi, among others, are trademarks of InVision Technologies, Inc. or one of its subsidiaries in the United States and other countries.   InVision, Quantum Magnetics, QScan and Yxlon among others, are registered trademarks marks of InVision Technologies, Inc. or one of its subsidiaries in the United States.



 

PART I.  FINANCIAL INFORMATION

 

Item 1.  Financial Statements

 

InVision Technologies, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share data)

(Unaudited)

 

 

 

June 29,
2003

 

December 31,
2002

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

162,977

 

$

159,736

 

Accounts receivable, net

 

64,411

 

146,295

 

Inventories

 

80,323

 

64,764

 

Deferred income taxes

 

20,648

 

20,889

 

Other current assets

 

9,340

 

15,811

 

Total current assets

 

337,699

 

407,495

 

Property and equipment, net

 

9,750

 

7,225

 

Deferred income taxes

 

812

 

1,050

 

Intangible assets, net

 

32,235

 

1,603

 

Other assets

 

1,816

 

414

 

Total assets

 

$

382,312

 

$

417,787

 

Liabilities and stockholders’ equity

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

$

15,217

 

$

28,477

 

Accrued liabilities

 

62,194

 

65,364

 

Deferred revenue

 

14,828

 

86,284

 

Short-term debt

 

5,588

 

184

 

Current maturities of long-term obligations

 

271

 

112

 

Total current liabilities

 

98,098

 

180,421

 

Long-term obligations

 

2,303

 

653

 

 

 

 

 

 

 

Commitments and contingencies (see Note 8)

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

Preferred stock, $0.001 par value, 5,000,000 shares authorized;
no shares issued and outstanding

 

 

 

Common stock, $0.001 par value, 60,000,000 shares authorized;
17,495,000 and 17,243,000 shares issued; 17,260,000 and 17,008,000 shares outstanding

 

17

 

17

 

Additional paid-in capital

 

169,659

 

166,243

 

Deferred stock compensation expense

 

(339

)

(406

)

Accumulated other comprehensive loss

 

(1,450

)

(1,783

)

Retained earnings

 

116,218

 

74,836

 

Treasury stock, at cost (235,000 and 235,000 shares)

 

(2,194

)

(2,194

)

Total stockholders’ equity

 

281,911

 

236,713

 

Total liabilities and stockholders’ equity

 

$

382,312

 

$

417,787

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

1



 

InVision Technologies, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 29,
2003

 

June 30,
2002

 

June 29,
2003

 

June 30,
2002

 

Revenues:

 

 

 

 

 

 

 

 

 

Product revenues

 

$

74,995

 

$

62,001

 

$

227,809

 

$

88,096

 

Service revenues

 

11,513

 

3,423

 

20,422

 

6,889

 

Contract research and development revenues

 

2,919

 

3,002

 

6,364

 

6,639

 

Total revenues

 

89,427

 

68,426

 

254,595

 

101,624

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues:

 

 

 

 

 

 

 

 

 

Product costs

 

44,452

 

35,007

 

129,126

 

49,924

 

Service costs

 

7,167

 

2,994

 

12,167

 

5,308

 

Contract research and development costs

 

1,933

 

1,989

 

4,069

 

4,532

 

Total cost of revenues

 

53,552

 

39,990

 

145,362

 

59,764

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

35,875

 

28,436

 

109,233

 

41,860

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

7,646

 

4,718

 

15,001

 

8,030</